-
The ASAM Weekly for January 14th, 2025
Review of Evidence on Alcohol and HealthFull story
Recent and Past Issues
-
ASAM Weekly for August 29th, 2023
Marijuana and hallucinogen use, binge drinking reached historic highs among adults 35 to 50Full story -
ASAM Weekly for August 22nd, 2023
Perceptions of Safety of Daily Cannabis vs Tobacco Smoking and Secondhand Smoke Exposure, 2017-2021Full story -
ASAM Weekly for August 15th, 2023
The Future of Addiction Treatment Lies in Narrowing the Treatment GapFull story -
Guest Editorial: The Future of Addiction Treatment Lies in Narrowing the Treatment Gap
In the time of the worst overdose crisis in American history, those of us who work in the field of addiction medicine have the responsibility of bringing treatment to where patients with addiction are. The addiction treatment gap refers to the approximately 94% of people with one or more DSM-5 defined substance use disorders (SUDs) who did not receive any addiction treatment (according to the SAMHSA鈥檚 National Survey on Drug Use and Health (NSDUH) conducted in 2021).Full story -
ASAM Weekly for August 8th, 2023
ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use DisorderFull story -
ASAM Weekly for August 1st, 2023
Guest Editorial by David A. Gorelick, MD, PhD, DLFAPA, FASAMFull story -
Guest Editorial: The Association of Cannabis Potency with Adverse Psychiatric Effects of Cannabis
Cannabis potency, the content of 鈭9-tetrahydrocannabinol (THC), usually expressed as the percentage of dry weight, has increased substantially worldwide over the past four decades [1]. This higher potency poses a risk of increased harms because of evidence of a positive association between cannabis potency and adverse psychiatric effects from long-term cannabis use. This article reviews the evidence for this association.Full story -
ASAM Weekly for July 25th, 2023
Remove Arbitrary Barrier to Evidence-based Treatment for Stimulant Use DisorderFull story -
Guest Editorial: Remove Arbitrary Barrier to Evidence-based Treatment for Stimulant Use Disorder
Although the current overdose crisis in the US is almost universally referred to as the 鈥渙pioid鈥 or 鈥渇entanyl crisis鈥1,2, the overdose death rate associated with psychomotor stimulants including methamphetamine and cocaine has also dramatically increased in recent years.Full story -
ASAM Weekly for July 18th, 2023
Questioning the Right to Pain Relief and Its Role in the Opioid EpidemicFull story
This Week in Addiction Medicine Podcast
A weekly audio summary and podcast of the ASAM Weekly
The ASAM Weekly
Editors & Staff
Editor-in-Chief: Nicholas Athanasiou, MD, MBA, DFASAM
Emeritus Editor: William Haning, MD, DFAPA, DFASAM
Publications Chair: Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors: Brandon
Aden, MD, Jack Woodside, MD, John A. Fromson, MD
Please direct customer service inquiries and comments to: ASAMWeekly@ASAM.org
The ASAM Weekly
Advertiser Services & Sales
Ad space is limited and available on a first-paid, first-published basis. To assure your ad will run in the specific issue you select, Insertion Orders must be signed by an authorized person in your organization and accepted by your customer service representative before taking the advertising units out of the active sales inventory. Payment must be received prior to the run date for an ad. Insertion Orders provide several options for payment in full including all major credit cards or check. Pre-approved billing must be arranged directly by an ASAM representative.
To learn more about advertising opportunities
Contact: Claire Rasmussen <crasmussen@asam.org>